-1768251348562.webp&w=3840&q=75)
2025 MaTOS Lung | Session XI | Keynote Presentation: Next Generation Approaches for Tailoring Treatments for EGFR and HER-2 Mutant NSCLC
Overview
Dr. Heymach reviewed lung cancer treatment evolution, stressing next-gen strategies beyond single mutations, co-mutation complexity, resistance, and promising new EGFR/HER2-targeted drugs.
Target Audience
Physicians
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
John Heymach, MD, PhD
Date of Release
January 9th, 2026
-1769196766441.webp&w=3840&q=75)
-1769196674841.webp&w=3840&q=75)